These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24919593)

  • 1. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
    Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
    BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
    Huang YT; Li FF; Ke C; Li Z; Li ZT; Zou XF; Zheng XX; Chen YP; Zhang H
    J Transl Med; 2013 Oct; 11():245. PubMed ID: 24090193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
    You YJ; Chen YP; Zheng XX; Meltzer SJ; Zhang H
    Cancer Lett; 2012 Feb; 315(2):138-44. PubMed ID: 22099875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
    Ramaswamy B; Majumder S; Roy S; Ghoshal K; Kutay H; Datta J; Younes M; Shapiro CL; Motiwala T; Jacob ST
    Mol Endocrinol; 2009 Feb; 23(2):176-87. PubMed ID: 19095770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
    Ming F; Sun Q
    Mol Med Rep; 2017 Jul; 16(1):746-754. PubMed ID: 28586036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.
    Yu M; Lin G; Arshadi N; Kalatskaya I; Xue B; Haider S; Nguyen F; Boutros PC; Elson A; Muthuswamy LB; Tonks NK; Muthuswamy SK
    Mol Cell Biol; 2012 Oct; 32(19):3913-24. PubMed ID: 22851698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
    Motiwala T; Ghoshal K; Das A; Majumder S; Weichenhan D; Wu YZ; Holman K; James SJ; Jacob ST; Plass C
    Oncogene; 2003 Sep; 22(41):6319-31. PubMed ID: 14508512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
    Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST
    Clin Cancer Res; 2007 Jun; 13(11):3174-81. PubMed ID: 17545520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
    Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
    Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
    Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
    Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
    Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
    Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
    BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation and breast cancer: A way forward (Review).
    Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.
    Veeck J; Wild PJ; Fuchs T; Schüffler PJ; Hartmann A; Knüchel R; Dahl E
    BMC Cancer; 2009 Jul; 9():217. PubMed ID: 19570204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.
    Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S
    Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.